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Pildenafil Improves Coronary
rtery Patency in a Canine
odel of Platelet-Mediated Cyclic
oronary Occlusion After Thrombolysis
regory D. Lewis, MD,* Christian Witzke, MD,* Pedro Colon-Hernandez, MD,* J. Luis Guerrero,*
enneth D. Bloch, MD,*† Marc J. Semigran, MD*
oston, Massachusetts
OBJECTIVES We sought to assess the effect of sildenafil, a highly-specific type 5 phosphodiesterase (PDE5)
inhibitor, on platelet-mediated cyclic coronary flow reductions occurring in a canine model of
coronary thrombosis despite aspirin therapy.
BACKGROUND The PDE5 inhibitors augment the antithrombotic effects of nitric oxide in vitro and in vivo,
but it has been proposed that the PDE5 inhibitor sildenafil is prothrombotic.
METHODS Cyclic coronary flow reductions were induced in the left anterior descending coronary artery
by creation of a stenosis, endothelial injury, and thrombus formation followed by treatment
with aspirin, heparin, and tissue plasminogen activator. After an initial observation period,
dogs were treated with or without sildenafil (100 g/kg bolus followed by 4 g/kg/min
infusion).
RESULTS Cyclic coronary flow reductions ceased in five of six animals 18  5 min after initiation of
sildenafil but continued in all six control animals. The portion of the observation period
during which the coronary artery was patent increased from 52  9% to 83  5% after
sildenafil administration (p  0.008) but did not differ between the first and second
observation periods in untreated dogs (49 11% vs. 44 11%, respectively). Among animals
with plasma free sildenafil levels 20 nmol/l, cyclic coronary flow reductions were 73  12%
less frequent and the time to cessation of cycling 72 14% shorter than in animals with levels
20 nmol/l (p  0.05 for both). Sildenafil transiently decreased blood pressure 7  1% but
did not change heart rate. Sildenafil treatment reduced ex vivo thrombin-induced platelet
aggregation by 39  3% (p  0.005).
CONCLUSIONS Sildenafil improves coronary patency in a canine model of platelet-mediated coronary artery
thrombosis, likely via inhibition of platelet aggregation. (J Am Coll Cardiol 2006;47:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.0601471–7) © 2006 by the American College of Cardiology Foundation
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mlatelet-mediated thrombosis has a fundamental role in the
athogenesis of acute coronary syndromes (ACS) (1). Sev-
ral randomized clinical trials have demonstrated the effi-
acy of antiplatelet agents such as aspirin, thienopyridines,
nd glycoprotein (GP) IIb/IIIa receptor antagonists in the
reatment of ACS. However, aspirin may not eliminate
latelet-mediated reocclusion after thrombolysis (2). Fur-
hermore, patients with ST-segment elevation myocardial
nfarction resistant to the antithrombotic effects of clopi-
ogrel have recurrent cardiovascular events more frequently
han those in whom platelet aggregation is suppressed (3).
he more potent GP IIb/IIIa receptor antagonists improve
ardiovascular outcomes of patients with ACS and those
ndergoing percutaneous coronary interventions (4–6).
nfortunately, GP IIb/IIIa receptor antagonists markedly
rolong bleeding time and occasionally cause thrombocyto-
enia, resulting in a greater risk of clinical hemorrhage
From the *Cardiology Division and †Cardiovascular Research Center of the
epartment of Medicine, Massachusetts General Hospital and Harvard Medical
chool, Boston, Massachusetts. This work was supported by NHLBI grants HL-
0896 (to Dr. Bloch), HL-04021 (to Dr. Semigran), and a sponsored research
greement with Pfizer Inc., New York, New York.a
Manuscript received July 6, 2005; revised manuscript received November 3, 2005,
ccepted November 21, 2005.4–6). Hence, the exploration of other agents that alter
ignaling pathways for platelet activation is needed to
mprove the safety and efficacy of antiplatelet therapy.
The effect of altering the intracellular concentration of
he second messenger cyclic guanosine monophosphate
cGMP) on platelet activation appears to vary depending on
he specific activators or inhibitors of cGMP synthesis
tudied. Nitric oxide (NO) donor compounds increase
ntracellular cGMP and inhibit platelet adhesion and ag-
regation (7,8). However, several agents that stimulate
latelet aggregation, including thrombin, collagen, epineph-
ine, and adenosine monophosphate, also have been shown
o increase platelet cGMP (reviewed in 9). Furthermore,
ifferent cGMP analogs appear to either promote (10,11) or
nhibit platelet aggregation (12,13).
Type 5 phosphodiesterase (PDE5) hydrolyzes cGMP to
elatively inactive GMP and is present in numerous cell
ypes, including platelets and vascular smooth muscle cells
14). We previously used a canine model of coronary artery
hrombosis superimposed on endothelial damage and high-
rade stenosis to demonstrate that two PDE5 inhibitors,
aprinast and dipyridamole, did not inhibit platelet-
ediated thrombosis after thrombolysis when administered
lone but were able to markedly augment the antithrom-
b
a
t
s
a
t
M
C
b
c
G
o
U
t
i
t
s
m
a
p
i
g
p
t
w
i
a
S
p
A
E
c
h
a
w
d
(
t
e
p
w
t
d
t
w
c
a
i
a
d
m
3
p
C
i
fl
E
m
o
s
s
r
r
c
4
a
p
7
w
t
a
C
a
p
A
c
m
c
t
5
m
p
m
M
p
s
w
c
t
c
C
c
m
t
A
1472 Lewis et al. JACC Vol. 47, No. 7, 2006
Sildenafil Improves Coronary Artery Patency April 4, 2006:1471–7otic effects of inhaled NO (15). Sildenafil is a clinically
vailable PDE5 inhibitor with greater specificity and po-
ency than either dipyridamole or zaprinast (16). Thus, we
ought to determine the effect of sildenafil on coronary
rtery patency in a canine model of platelet-mediated
hrombosis despite aspirin therapy.
ETHODS
anine model of coronary artery occlusion after throm-
olysis. These investigations were approved by the Sub-
ommittee on Research Animal Care of the Massachusetts
eneral Hospital and were in compliance with the “Position
f the American Heart Association on Research Animal
se,” adopted in 1984.
Adult mongrel dogs (weight 18 to 22 kg) were anesthe-
ized with intravenous pentobarbital (30 mg/kg), tracheally
ntubated, and mechanically ventilated. Supplemental pen-
obarbital was given as needed to maintain general anesthe-
ia. The fraction of inspired oxygen (FiO2) was adjusted to
aintain PaO2 80 mm Hg, as determined by periodic
rterial blood gas measurements. A left thoracotomy was
erformed in the fifth intercostal space, and dogs were
nstrumented for intracoronary infusion, electrocardio-
raphic monitoring, and measurement of systemic blood
ressure as previously described (17). A 2.5-cm segment of
he proximal left anterior descending coronary artery (LAD)
as isolated. A 0.7-mm internal diameter catheter was then
nserted into a side-branch of the isolated LAD segment,
nd an ultrasonic flow probe (T106 Flowmeter, Transonic
ystems, Ithaca, New York) was placed on the proximal
ortion of the artery for continuous blood flow monitoring.
2-mm wide plastic wire tie (Massachusetts Gas and
lectric Supply, Boston, Massachusetts) was progressively
onstricted around the distal end of the segment until the
yperemic response to mechanical occlusion was eliminated
nd an approximately 50% reduction in initial blood flow
as achieved. Angiographic study has shown that this
egree of constriction decreases luminal diameter by 90%
18). The rate of coronary blood flow after LAD constric-
ion was considered “baseline” flow.
The isolated segment of the LAD was traumatized by
xternal compressions to damage the endothelium and
romote thrombus adherence. Thrombus was formed
Abbreviations and Acronyms
ACS  acute coronary syndromes
CAPR coronary artery patency ratio
CFR  cyclic coronary flow reductions
cGMP cyclic guanosine monophosphate
GP  glycoprotein
LAD  left anterior descending coronary artery
MAP  mean systemic arterial blood pressure
NO  nitric oxide
PDE5  type 5 phosphodiesteraseithin the LAD segment by adding 0.1 ml of thrombin co 0.3 ml of previously sampled blood through the
iagonal branch catheter after applying snares proximal
o the constriction site and distal to the probe. Snares
ere released after 10 min of arterial occlusion and, in all
ases, the presence of thrombus was confirmed by lack of
rterial blood flow through the segment and by visual
nspection. Ten minutes later, heparin (40 U/kg) and
spirin (2.5 mg/kg) were administered intravenously. Ad-
itional heparin (5 to 20 U/kg) was administered every 20
in as needed to maintain an ACT of 150 to 200 s. After
0 min of stable occlusion, a 0.45-mg/kg bolus of tissue
lasminogen activator (Genentech, South San Francisco,
alifornia) was administered intravenously at 15-min
ntervals until coronary artery patency (25% of baseline
ow) was achieved.
xperimental protocol. Achievement of coronary patency
arked the starting point for the first of two 60-min
bservation periods. The first 60-min observation period
erved as a pretreatment period for all 12 animals. For the
econd 60-min observation period, dogs were assigned
andomly to receive no additional therapy (n  6) or to
eceive sildenafil (100 g/kg in normal saline over the
ourse of 2 min followed by a continuous infusion of
g/kg/min, n  6). This dose of sildenafil was chosen in
n effort to mimic peak plasma concentrations of sildenafil
roduced after the administration of a 50-mg oral dose to a
0-kg human being (19).
Systemic arterial pressure and coronary artery blood flow
ere measured continuously. A cyclic coronary flow reduc-
ion (CFR) was defined as reocclusion of the coronary artery
fter a spontaneous increase to 25% of baseline flow.
oronary artery patency ratio (CAPR) was the fraction of
n observation period during which the coronary artery was
atent.
ctivated clotting time (ACT), hemoglobin, and platelet
ount measurements. Activated clotting time measure-
ents were performed using an Hemochron 800 dual-well
oagulation timer and FTCA 510 reaction tubes (Interna-
ional Technidyne, Edison, New Jersey) every 20 min, and
to 20 U/kg boluses of heparin were administered to
aintain ACT between 150 and 200 s. Hemoglobin and
latelet counts were measured from samples taken at the
idpoints of periods one and two.
easurement of ex vivo whole-blood aggregation and
lasma sildenafil levels. In the group of dogs treated with
ildenafil, thrombin-induced ex vivo platelet aggregation
as measured before any arterial manipulation or pharma-
otherapy (baseline) and at the midpoints of periods one and
wo. Blood (3 ml) was collected in tubes containing a final
oncentration of 3.13% (weight/volume) sodium citrate.
itrated blood (500 l) was then transferred into cuvettes
ontaining 490 l of saline and maintained at 37°C with
agnetic stirring (1,000 rpm) in an impedance aggregome-
er (Model 440, Chronolog, Havertown, Pennsylvania).
fter reaching a stable baseline, the aggregometer was
alibrated such that full-scale deflection was 40 Ohms.
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April 4, 2006:1471–7 Sildenafil Improves Coronary Artery Patencyggregation was induced by the addition of 10 l of
00 U/ml thrombin solution. The extent of whole blood
ggregation was assessed as the maximum impedence
eached during a 6-min observation period after exposure
o thrombin. Thrombin was used as the agonist for
ssessment of ex vivo whole blood platelet aggregation in
his model because pilot studies using thrombin (2 U/ml),
DP (10 mol/l), or collagen (5 g/ml) led to the
bservation that thrombin produced the most consistent
latelet aggregation.
Plasma samples were collected after 30 min of sildenafil
nfusion and stored at 70°C. Plasma free sildenafil con-
entrations were measured by high-performance liquid
hromatography as described previously (20).
tatistical analysis. All data are reported as the mean
alue SEM. The significance of changes in CAPR and
FR, as well as hemodynamic and hematologic variables
rom period 1 to period 2, was determined by a paired
tudent t test. The significance of the changes in platelet
ggregability at baseline and during periods one and two was
etermined using a repeated-measures analysis of variance
able 1. Characteristics of the Canine Coronary Artery Model
f Reocclusion After Thrombosis and Thrombolysis
Parameter
Control
(n  6)
Sildenafil
(n  6)
nitial coronary blood flow (ml/min) 17.0  1.7 14.4  1.7
oronary blood flow after application of
constrictor (ml/min)
9.4  1 7.4  1
umber of tPA boluses before reperfusion 1.3  0.2 1  0
FRs during period 1, cycles/h 5.3  0.6 4.2  1.0
APR during period 1, % 49  11 52  9
ata are presented as the mean value SEM. There was no difference in any of these
ariables between the two groups.
CAPR  fraction of the pre-treatment period during which the coronary artery
as patent; CFRs  frequency of cycle flow reductions; tPA  tissue plasminogen
ctivator.
igure 1. Schematic representation of the coronary artery patency status
uring an initial 60-min period (period 1). During the second period (perio
hereas six control animals received no further treatment. White areas represe
cclusion.ollowed by the Neuman-Keuls procedure. A value of p 
.05 was considered significant.
ESULTS
haracteristics of the canine model of platelet-mediated
yclic coronary occlusion after thrombolysis. The char-
cteristics of the canine model before treatment with or
ithout sildenafil (period 1), including the frequency of
FRs and the CAPR, are summarized in Table 1. Appli-
ation of the external constrictor reduced LAD blood flow
y 49  5% in the sildenafil group and by 44  6% in the
ontrol group. There were no significant differences be-
ween the two experimental groups in the LAD blood flow
fter application of the constrictor, the number of tissue
lasminogen activator boluses required to establish coronary
atency (Table 1), or in the ACT (data not shown). Cyclic
oronary flow reduction frequency and CAPR during period
also did not differ between the two experimental groups.
ffects of sildenafil on coronary artery patency. Left
nterior descending coronary artery patency after thrombol-
sis during periods 1 and 2 is represented schematically for
ndividual animals in Figure 1. Black areas indicate intervals of
oronary occlusion (blood flow 25% of post-constriction
aseline), and white areas indicate intervals of patency. In
ogs that did not receive sildenafil, CFR frequency during
eriods 1 and 2 did not differ (5.3  0.8 cycles/h and 4.2 
.0 cycles/h, respectively). In contrast, CFRs ceased in five
f six animals 18 5 min after the initiation of sildenafil.
he number of CFRs in period 2 tended to be fewer in
ildenafil-treated animals than in control animals (2.4 0.8
s. 4.2  1.0, p  0.06) In dogs that did not receive
ildenafil, the CAPR did not differ from period 1 to period
(49  11% vs. 44  11%). However, after the adminis-
ration of sildenafil, CAPR increased from 52  9% during
dogs during two sequential observation periods. All dogs were observed
six animals received sildenafil (50 g/kg bolus followed by 4 g/kg/min),of 12
d 2),nt coronary patency (flow 25% of baseline), and black areas represent
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Sildenafil Improves Coronary Artery Patency April 4, 2006:1471–7eriod 1 to 83  5% during period 2 (p  0.01) after the
nitiation of sildenafil (Fig. 2). CAPR during period 2 was
reater in sildenafil-treated dogs than in control dogs (p 
.008).
The average free plasma sildenafil levels attained 30 min
fter administration of the bolus and initiation of the
nfusion were 30.3  6.6 nmol/l. Among dogs treated with
ildenafil, CFRs were less frequent in the three dogs with
ree plasma sildenafil levels 20 nmol/l (Fig. 1, dog #7, #8,
nd #11) than in those dogs with sildenafil levels less than
0 nmol/l (1.0  0.4 vs. 3.7  0.5, respectively, p  0.05).
n addition, the time to cessation of cycling was shorter in
he dogs with free plasma sildenafil levels 20 nmol/l
9.8  3.5 min) than in those with levels 20 nmol/l
32.3  2.3 min, p  0.05).
igure 2. Coronary artery patency ratio (CAPR; fraction of an observed
bservation period during which the coronary flow was 25% of imme-
iate postconstriction flow). Dogs in the control group (n  6) were given
o additional treatment in period 2. Dogs in the sildenafil group were given
00 g/kg sildenafil bolus followed by an infusion of 4 g/kg/min during
eriod 2. *p  0.008; #p  0.007.
igure 3. Effects of aspirin and sildenafil on platelet aggregation. (A) Throm
t 30 min, and sildenafil and aspirin [SASA] at 90 min) relative to b
ggregometry (n  6 dogs). *p  0.05, ASA versus baseline. *#p  0.05, ASA
ggregation recordings in dog 9.ffects of sildenafil on ex vivo whole-blood aggrega-
ion. In the group of dogs which were to be treated with
ildenafil, ex vivo thrombin-induced platelet activation was
4  2% lower at the midpoint of period 1 than at baseline
p  0.007), which likely was attributable to treatment with
spirin. Administration of sildenafil decreased ex vivo plate-
et activation by an additional 39  5% as measured at the
idpoint of period 2, compared with that observed at the
idpoint of period 1 (p  0.05) (Fig. 3A). Representative
latelet aggregation curves (dog #9) are shown in Fig 3B. In
ogs that were not treated with sildenafil, ex vivo thrombin-
nduced platelet activation at the midpoints of period 1 and
eriod 2 did not differ. The blood platelet and hemoglobin
oncentrations were unchanged during the two observation
eriods in both groups of dogs (Table 2).
ffects of sildenafil on arterial blood pressure and heart
ate. One minute after bolus administration of sildenafil, a
ransient decrease in mean systemic arterial blood pressure
MAP) from 97  6 mm Hg to 91  5 mm Hg was
bserved (Fig. 4, p  0.05). By 5 min after the initiation of
ildenafil, MAP had returned to pre-sildenafil levels, and
here was no further change in MAP during the remainder
f the 60-min sildenafil infusion period (Table 2). Heart
ate did not change following treatment with sildenafil.
ISCUSSION
his study was conducted to determine the effects of
ildenafil on platelet-mediated thrombosis in a well-
haracterized canine model of coronary artery thrombosis
fter thrombolysis (18). Our study demonstrates that intra-
enous sildenafil increased coronary artery patency, reduced
x vivo platelet aggregability, and stopped cyclic flow reduc-
ion in the majority of animals. We observed that dogs with
ree sildenafil levels 20 nmol/l (the average peak concen-
ration observed in patients after administration of a 50-mg
induced platelet aggregation during the treatment period (aspirin [ASA],
e aggregation in the pretreatment period, as determined by whole bloodbin-
aselinsildenafil versus each of the other groups. (B) Representative platelet
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April 4, 2006:1471–7 Sildenafil Improves Coronary Artery Patencyral dose of sildenafil) had fewer CFRs and a more rapid
essation of cyclic occlusion than did dogs with free silde-
afil levels 20 nmol/l.
Sildenafil is a specific inhibitor of PDE5, which is present
n a variety of cell types that contribute to vascular ho-
eostasis, including platelets and vascular smooth muscle
ells (21). Previous histologic studies in this canine model
ave demonstrated the presence of intracoronary platelet-
ich thrombus during cyclic occlusion (22), and other
tudies using this model have shown that cyclic occlusion is
educed only by antithrombotic agents that inhibit platelet
unction (23). These results, as well as the current observa-
ions that sildenafil administration inhibited ex vivo platelet
ggregation, are supportive of inhibition of platelet function
s the mechanism for the improvement in coronary patency
bserved during sildenafil administration. We cannot ex-
lude the possibility that coronary vasodilation contributed
o our observation that sildenafil improved coronary pa-
ency; however, in patients with coronary disease undergo-
ng PCI, sildenafil did not change coronary cross-sectional
rea or blood flow (24).
Nitric oxide-donor compounds and inhaled NO increase
latelet cGMP concentrations, decrease platelet aggregation
n vitro, and inhibit thrombosis in vivo. Other agents that
ctivate cGMP synthesis by soluble guanylate cyclase also
nhibit platelet aggregation in vitro and thrombosis in vivo,
ncluding YC-1 (25), BAY 41-8543 (26), and BAY 41-
272 (27). It is probable that the antithrombotic effects of
igure 4. Effect of the bolus administration of sildenafil on mean arterial
lood pressure (MAP). There was a transient fall in MAP within 1 min of
he bolus administration of sildenafil that persisted for 3 min. The MAP 5
Table 2. Blood Pressure and Hematologic Valu
Cont
Period 1
Mean arterial pressure (mm Hg) 78  5
Hemoglobin (g/100 ml) 7.8  0.4
Platelet count (thousands/mm3) 252  11
Data are presented as the mean value  SEM. There was np
in after sildenafil administration did not differ from that at the end of
eriod 1. *p  0.05.ildenafil are attributable to its ability to increase cGMP
oncentrations in platelets by inhibiting PDE5.
The PDE5 inhibitors have been shown to reduce platelet
ggregation in an animal model of endothelial injury (28),
nd reduce human ex vivo platelet aggregability (29). PDE5
nhibitors also augment the ability of NO-donor com-
ounds to decrease platelet aggregation in vitro (17) and
latelet-mediated thrombosis in vivo (29). The clinical
tility of the concomitant administration of PDE5 inhibi-
ors and NO donor compounds to prevent thrombosis is
imited by severe systemic arterial hypotension (30). We
ecently reported that although two PDE5 inhibitors, di-
yridamole and zaprinast, did not inhibit coronary throm-
osis and thrombolysis when administered alone, they
arkedly augmented the anti-thrombotic effects of inhaled
O (15) without systemic hypotension. The ability of
ildenafil to inhibit coronary thrombosis in the absence of
xogenous NO is most likely because it is a more specific
nd potent inhibitor of PDE5 than either dipyridamole or
aprinast. The dose of sildenafil that was administered in
his study produced a plasma concentration that exceeded
he IC50 for PDE5 (3.5 nmol/l), whereas the doses of
ipyridamole and zaprinast administered in the previous
tudy (15) would not be expected to achieve the IC50 of
hese agents for PDE5, which are 500- (31) and 250-fold
13) greater than sildenafil, respectively. It is probable that
oses of dipyridamole sufficient to achieve a level of PDE5
nhibition similar to that achieved by sildenafil would block
denosine reuptake, potentially leading to hypotension (32).
ecause concentrations of zaprinast necessary to block
DE5 activity are likely to inhibit type 1 phosphodiesterase
16), it is probable that doses of zaprinast sufficient to
nhibit thrombosis would increase intracellular cAMP in
ardiac and vascular smooth muscle, leading to tachycardia
nd vasodilation.
It has previously been reported that sildenafil did not
mprove coronary patency in a canine model of coronary
hrombosis (33). In an effort to mimic the thrombogenic
nvironment of clinical ACS, our model differs from that
reviously used (33) because aspirin was administered to the
nimals at the beginning of the study. Thus, the platelet
nhibitory effects observed in the current study may be the
esult of a greater inhibitory role for cGMP in platelets no
onger subject to activation through the arachadonic acid
athway. Further study of the role of cGMP signaling on
uring the Two Observation Periods
 6) Sildenafil (n  6)
Period 2 Period 1 Period 2
78  5 98  6 93  4
7.4  0.8 7.9  0.3 7.8  0.3
249  9 310  24 285  19
rence in any of these variables between the two groups.es D
rol (nlatelet aggregability in the presence of cyclooxygenase
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Sildenafil Improves Coronary Artery Patency April 4, 2006:1471–7nhibition may clarify the reason for the differing results in
he two studies.
Li et al. (11) have reported that concurrent addition of
GMP analogs and sildenafil potentiated ristocetin- or
hrombin-induced platelet aggregation in vitro when the
roaggregatory stimulus was administered within 10 min of
ildenafil exposure. These investigators proposed that the
latelet responses to cGMP are biphasic, initially promoting
ggregation and subsequently limiting thrombus formation.
n the present study, we observed an inhibitory effect of
ildenafil on ex vivo platelet aggregation 30 min after its
dministration. Furthermore, cessation of in vivo cyclic
cclusion did not occur until 18 5 min after sildenafil was
iven. Although we did not measure platelet aggregability
arly after sildenafil administration, we did not observe an
arly increase in CFR or a reduction in CAPR during the
nitial 30 min after sildenafil administration. Our observa-
ions are consistent with the antiaggregatory effect of
ncreased platelet cGMP concentration observed in vitro
13), and in other models of cyclic coronary occlusion
ausing myocardial ischemia (7).
linical implications. Cases of acute myocardial infarction
fter the use of sildenafil have been reported (34,35). The
esults of this study suggest that these events are unlikely to
e attributable to a prothrombotic effect of this drug and are
n agreement with a recent case-control study of Mittleman
t al (36) and a recent report from the U.S. Food and Drug
dministration (37) that did not find a higher incidence of
yocardial infarction or other thrombotic events with
ildenafil use when compared with expected rates in a
imilar patient population. Our observation of an antiplate-
et effect of sildenafil also is consistent with that of Halcox
t al. (38), who observed that sildenafil decreased platelet
ggregation in patients with CAD.
In the animal model we used, aspirin reduced ex vivo
latelet aggregation by 24%; however, cyclic coronary oc-
lusion continued, which likely is attributable to the pres-
nce of a potent thrombotic stimulus of a partially lysed
hrombus at the site of a severe fixed coronary stenosis that
ay be caused by thrombin (2). In this study, the addition
f sildenafil to aspirin resulted in the cessation of cyclic
oronary occlusion and a 39% further reduction in ex vivo
latelet aggregation. Furthermore, agents that have previ-
usly been shown to be effective in this model, such as
bciximab and tirofiban, have proven effective for the
reatment of ACS (23). Our results suggest that agents that
ugment intracellular cGMP, such as PDE5 inhibitors, merit
urther exploration as adjunctive therapy in ACS and other
yndromes associated with platelet-mediated thrombosis.
tudy limitations. Our observations of the benefits of silde-
afil administration in a canine model of platelet-mediated
hrombosis after thrombolysis may not be applicable to the risk
f initial thrombotic coronary occlusion occurring in patients at
isk for ACS. Furthermore, the potential application of our
bservations to the treatment of ACS is limited by the current
se of nitrate therapy for these patients. The use of PDE5nhibitors concomitantly with nitrates is contraindicated be-
ause of the propensity of this combination to cause profound
ypotension. Although we observed coronary patency in our
tudy for 60 mins after the initiation of administration of
ildenafil, the duration of action of this effect was not assessed
nd may be limited by the 4-h half-life of sildenafil. Although
achyphylaxis to the hemodynamic effects of sildenafil has not
een reported in patients with pulmonary hypertension (39),
he possibility that this will limit its use as an antiplatelet
herapy remains to be explored.
onclusions. Sildenafil improves coronary patency in an in
ivo model of platelet-mediated thrombosis and inhibits ex
ivo platelet aggregation despite aspirin therapy. These
esults suggest that blockade of cGMP hydrolysis may
epresent a novel target for antiplatelet therapy.
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